Prothena | PRTA - Sales Revenues

Stock Price
8.45
Daily Change
-0.44 -4.95%
Monthly
-5.80%
Yearly
-41.48%
Q1 Forecast
8.55

Prothena reported $2.42M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 278.6M 14M Sep/2025
Agios Pharmaceuticals USD 12.9M 450K Sep/2025
ALKERMES USD 394.2M 3.5M Sep/2025
Alnylam Pharmaceuticals USD 1.25B 476.31M Sep/2025
Amgen USD 9.9B 340M Dec/2025
Biogen USD 2.53B 70M Sep/2025
BioMarin Pharmaceutical USD 776M 49M Sep/2025
Exelixis USD 597.8M 29.5M Sep/2025
Incyte USD 1.37B 310M Sep/2025
Ionis Pharmaceuticals USD 157M 295M Sep/2025
MacroGenics USD 72.84M 50.6M Sep/2025
Neurocrine Biosciences USD 794.9M 107.4M Sep/2025
Prothena USD 2.42M 2M Sep/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Ultragenyx Pharmaceutical USD 160M 6.5M Sep/2025
Vertex Pharmaceuticals USD 3.08B 120M Sep/2025